Sector News

AstraZeneca appoints Professor Nazneen Rahman to its Board

June 2, 2017
Life sciences

AstraZeneca announced that, effective 1 June 2017, the Board has appointed Professor Nazneen Rahman as a Non-Executive Director of AstraZeneca PLC. On appointment, Professor Rahman also becomes a member of the Science Committee.

Professor Nazneen Rahman is Head of the Division of Genetics and Epidemiology at the Institute of Cancer Research (ICR), London; Head of the Cancer Genetics Unit at the Royal Marsden NHS Foundation Trust; and Director of the TGL clinical gene testing laboratory at the ICR. She qualified in medicine from Oxford University and holds a PhD in molecular genetics, according to AstraZeneca.

Professor Rahman’s research harnesses her scientific and clinical expertise to identify and clinically implement human disease genes. She has a strong focus on cancer predisposition genes, in which she is an internationally-recognised expert and has discovered many such genes during her career, particularly for breast, ovarian and childhood cancers.

Elected as a Fellow of the Academy of Medical Sciences in 2010, Professor Rahman is a member of the scientific advisory boards of Genomics plc and the Centre for Molecular Medicine Norway, as well as the advisory board of Wellcome Open Research.

Professor Rahman has a strong commitment to open science and science communication and has garnered numerous awards, including a CBE in the 2016 Queen’s birthday honours in recognition of her contribution to medical sciences.

Leif Johansson, Chairman of AstraZeneca, said: “We are delighted to welcome Professor Rahman to our Board and Science Committee. She brings world-renowned expertise in genetic research with a focus on cancer, which is a strategic therapy area for our business.”

In relation to Professor Rahman’s appointment, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority’s Listing Rules.

Source: The Financial

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.

Send this to a friend